Over a 2‐year period from January 1991 to December 1992, second‐trimester maternal
serum screening for Down's syndrome using alpha‐fetoprotein (aFP), human chorionic …

OBJECTIVES--To assess the implementation of antenatal screening for Down's syndrome in
practice, using individual risk estimates based on maternal age and the three serum …

OBJECTIVE--To appraise a new method of prenatal screening for Down's syndrome based
on maternal serum concentrations of alpha fetoprotein, unconjugated oestriol, and human …

Objective To investigate the effect of using a routine ultrasound estimate of gestational age
and maternal weight adjustment on maternal serum alpha‐fetoprotein (AFP), unconjugated …

Objectives-To evaluate the introduction to two health districts of an antenatal serum
screening programme for Down's syndrome using the triple test-measurement of a …

The possibility of improving the effectiveness of antenatal screening for Down's syndrome by
measuring human chorionic gonadotrophin concentrations in maternal serum during the …

The value of measuring the separate sub‐units of human chorionic gonadotrophin (free α‐
hCG and free β‐hCG) instead of total hCG together with alpha‐fetoprotein (AFP) and …

The median maternal serum unconjugated oestriol level between 13 and 27 weeks
gestation in 77 pregnancies associated with Down's syndrome was lower than the median …

Second‐trimester maternal serum screening for fetal Down's syndrome is well established in
many Western countries. Its usefulness and acceptability is unknown in the Asian countries …

The effectiveness of maternal serum alpha-fetoprotein, unconjugated oestriol, and human
chorionic gonadotrophin in screening for Down's syndrome (DS) was evaluated on 840 …